Neumora Therapeutics Inc. (NASDAQ: NMRA) is -46.86% lower on its value in year-to-date trading and has touched a low of $9.35 and a high of $21.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NMRA stock was last observed hovering at around $9.59 in the last trading session, with the day’s loss setting it -0.53%.
Currently trading at $9.06, the stock is -27.68% and -39.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing -5.53% at the moment leaves the stock -34.65% off its SMA200. NMRA registered a gain of -16.03% in past 6-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -28.15% loss in the last 1 month and extending the period to 3 months gives it a -40.00%, and is -14.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.76% over the week and 7.72% over the month.
Neumora Therapeutics Inc. (NMRA) has around 124 employees, a market worth around $1.44B and $0.00M in sales. Distance from 52-week low is -3.10% and -56.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.10%).
The EPS is expected to grow by 58.57% this year
The shares outstanding are 158.83M, and float is at 53.02M with Short Float at 11.07%.
Neumora Therapeutics Inc. (NMRA) Insider Activity
The most recent transaction is an insider purchase by Burow Kristina, the company’s Director. SEC filings show that Burow Kristina bought 3,357 shares of the company’s common stock on Nov 14 ’23 at a price of $11.98 per share for a total of $40217.0. Following the purchase, the insider now owns 4.13 million shares.
Neumora Therapeutics Inc. disclosed in a document filed with the SEC on Nov 14 ’23 that ARCH Venture Partners XII, LLC (10% Owner) bought a total of 3,357 shares of the company’s common stock. The trade occurred on Nov 14 ’23 and was made at $11.98 per share for $40217.0. Following the transaction, the insider now directly holds 4.13 million shares of the NMRA stock.
Still, SEC filings show that on Nov 13 ’23, ARCH Venture Partners XII, LLC (10% Owner) acquired 31,653 shares at an average price of $11.75 for $0.37 million. The insider now directly holds 4,127,850 shares of Neumora Therapeutics Inc. (NMRA).
